zoledronic acid + teriparatide

Zoledronic acid + teriparatide is a combination therapy used primarily in the management of osteoporosis, especially in postmenopausal women at high risk for fracture. Zoledronic acid is a potent intravenous bisphosphonate that inhibits bone resorption by osteoclasts, primarily through inhibition of farnesyl pyrophosphate synthase in the mevalonate pathway, leading to osteoclast apoptosis and reduced bone turnover. Teriparatide is a recombinant human parathyroid hormone (1-34), and functions as an anabolic agent, stimulating osteoblast-mediated bone formation. Combination therapy aims to leverage both the anti-resorptive effects of zoledronic acid and the bone-forming action of teriparatide, resulting in increased bone mineral density at both the spine and hip compared to either agent alone. The combination is under investigation and not approved as a fixed-dose combination product; it is instead used as co-administration of the two drugs, often with zoledronic acid administered intravenously once yearly and teriparatide given as a daily subcutaneous injection. Clinical studies show a larger and more rapid increment in bone density when both are used together, though there is some evidence that simultaneous use may blunt some anabolic effects of teriparatide; simultaneous or sequential regimens are both studied[1][3][5].